LB
The startup develops bacteriophage-based therapies that utilize CRISPR-Cas3 technology to target and eliminate pathogenic bacteria in the human body. This approach enables rapid treatment initiation by physicians, leading to improved medical outcomes for patients with bacterial infections.
Morrisville, United States
Updated 2 months ago
Funding
$105.3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- The startup develops bacteriophage-based therapies that utilize CRISPR-Cas3 technology to target and eliminate pathogenic bacteria in the human body. This approach enables rapid treatment initiation by physicians, leading to improved medical outcomes for patients with bacterial infections.